Spero Therapeutics reported a net loss of $9.6 million for Q2 2026, compared to $1.7 million in the prior year period, with no revenue recognized as deferred amounts were fully recognized previously. The company secured $105 million in non-recourse royalty financing backed by future Utebzi proceeds from GSK, extending its cash runway into late 2029. Spero also entered an exclusive license agreement for SP001 with Innovent Biologics and appointed Debra Zack as Chief Medical Officer. Additionally, the FDA approved Utebzi for complicated urinary tract infections. Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation.
